Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy
Guru Sonpavde; Gregory R. Pond; Stephanie Mullane; Ana A. Ramirez; Nicholas J. Vogelzang; Andrea Necchi; Thomas Powles; Joaquim Bellmunt
Author Information: UAB Comprehensive Cancer Center
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.